Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment

Proceedings of the National Academy of Sciences of the United States of America

Volumn 100, Issue 23, 2003, Pages 13668-13673

  Marino, Michael J ^a   Williams Jr , David L ^a   O'Brien, Julie A ^a   Valenti, Ornella ^a   McDonald, Terrence P ^a   Clements, Michelle K ^a   Wang, Rulping ^a   DiLella, Anthony G ^a   Hess, J Fred ^a   Kinney, Gene G ^a   Conn, P Jeffrey ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 PHOSPHONOBUTYRIC ACID; 7 (HYDROXYLIMINO)CYCLOPROPACHROMEN 1A CARBOXAMIDE ETHYL ESTER; ESTER DERIVATIVE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR AGONIST; N PHENYL 7 (HYDROXYLIMINO)CYCLOPROPA[B]CHROMEN 1A CARBOXAMIDE; RESERPINE; UNCLASSIFIED DRUG;

AKINESIA; ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; GLOBUS PALLIDUS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; RAT; SYNAPTIC TRANSMISSION; TREATMENT INDICATION;

ALLOSTERIC SITE; ANIMALS; BENZOPYRANS; BRAIN; CELL LINE; CHROMONES; DOPAMINE; ELECTROPHYSIOLOGY; ESTERS; HUMANS; MALE; MODELS, BIOLOGICAL; MODELS, CHEMICAL; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SYNAPSES; TIME FACTORS;

ANIMALIA;

EID: 0345686620     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.1835724100     Document Type: Article

References (33)

1. Hassler, R. (1938) J. Psychol. Neurol. 48, 387-476.
2. Erhinger, H. & Hornykiewicz, O. (1960) Klin. Wochenschr. 38, 1236-1239.
3. Jankovic, J. (2002) Neurology 58, 19S-32S.
4. Fahn, S. (1999) Arch. Neurol. 56, 529-535.
5. Ahlskog, J. E. (2003) Neurology 60, 381-389.
6. Wichmann, T. & DeLong, M. R. (1998) Neurosurg. Clin. N. Am. 9, 223-236.
7. Lozano, A. & Carella, F. (2002) Parkinsonism Relat. Disord. 8, 455-458.
8. Marino, M., Valenti, O. & Conn, P. J. (2003) Drugs Aging 20, 377-397.
9. Valenti, O., Marino, M. J., Wittmann, M., Lis, E., DiLella, A. G., Kinney, G. G. & Conn, P. J. (2003) J. Neurosci. 23, 7218-7226.
10. Annoura, H., Fukunaga, A., Uesugi, M., Tatsouka, T. & Horikawa, Y. (1996) Bioorg. Med. Chem. Lett. 6, 763-766.
11. Lin, F. F., Varney, M., Sacaan, A. I., Jachec, C., Daggett, L. P., Rao, S., Flor, P., Kuhn, R., Kerner, J. A., Standaert, D., et al. (1997) Neuropharmacology 36, 917-931.
12. O'Brien, J. A., Lemaire, W., Chen, T.-B., Chang, R. S. L., Jacobsen, M. A., Ha, S. N., Lindsley, C. W., Schaffhauser, H., Sur, C., Pettibone, D. J., et al. (2003) Mol. Pharmacol. 64, 731-740.
13. Cooper, A. J. & Stanford, I. M. (2001) Neuropharmacology 41, 62-71.
14. Gereau, R. W. & Conn, P. J. (1995) J. Neurosci. 15, 6879-6889.
15. Macek, T. A., Winder, D. G., Gereau, R. W., Ladd, C. O. & Conn, P. J. (1996) J. Neurophysiol. 76, 3798-3806.
16. Bradley, S. R., Standaert, D. G., Rhodes, K. J., Rees, H. D., Testa, C. M., Levey, A. I. & Conn, P. J. (1999) J. Comp. Neurol. 407, 33-46.
17. Cai, Z., Saugstad, J. A., Sorensen, S. D., Ciombor, K. J., Zhang, C., Schaffhauser, H., Hubalek, F., Pohl, J., Duvoisin, R. M. & Conn, P. J. (2001) J. Neurochem. 78, 756-766.
18. Corti, C., Aldegheri, L., Somogyi, P. & Ferraguti, F. (2002) Neuroscience 110, 403-420.
19. Schoepp, D. D., Jane, D. E. & Monn, J. A. (1999) Neuropharmacology 38, 1431-1476.
20. Gasparini, F., Lingenhohl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., et al. (1999) Neuropharmacology 38, 1493-1503.
21. Litschig, S., Gasparini, F., Rueegg, D., Stoehr, N., Flor, P. J., Vranesic, I., Prezeau, L., Pin, J. P., Thomsen, C. & Kuhn, R. (1999) Mol. Pharmacol. 55, 453-461.
22. Valenti, O., Conn, P. J. & Marino, M. J. (2002) J. Cell. Physiol. 191, 125-137.
23. Knoflach, F., Mutel, V., Jolidon, S., Kew, J. N., Malherbe, P., Vieira, E., Wichmann, J. & Kemp, J. A. (2001) Proc. Natl. Acad. Sci. USA 98, 13402-13407.
24. Breysse, N., Baunez, C., Spooren, W., Gasparini, F. & Amalric, M. (2002) J. Neurosci. 22, 5669-5678.
25. Ossowska, K., Konieczny, J., Wolfarth, S., Wieronska, J. & Pilc, A. (2001) Neuropharmacology 41, 413-420.
26. Dawson, L., Chadha, A., Megalou, M. & Duty, S. (2000) Br. J. Pharmacol. 129, 541-546.
27. Bradley, S. R., Marino, M. J., Wittmann, M., Rouse, S. T., Awad, H., Levey, A. I. & Conn, P. J. (2000) J. Neurosci. 20, 3085-3094.
28. Messenger, M. J., Dawson, L. G. & Duty, S. (2002) Neuropharmacology 43, 261-271.
29. Awad-Granko, H. & Conn, P. J. (2001) Neuropharmacology 41, 32-41.
30. Wittmann, M., Marino, M. J., Bradley, S. R. & Conn, P. J. (2001) J. Neurophysiol. 85, 1960-1968.
31. Mathiesen, J. M., Svendsen, N., Brauner-Osborne, H., Thomsen, C. & Ramirez, M. T. (2003) Br. J. Pharmacol. 138, 1026-1030.
32. Urban, M. O., Hama, A. T., Bradbury, M., Anderson, J., Varney, M. A. & Bristow, L. (2003) Neuropharmacology 44, 983-993.
33. Magill, P. J., Bolam, J. P. & Bevan, M. D. (2000) J. Neurosci. 20, 820-833.